IQ-AI Limited (LON:IQAI) said its synthetic T1+C (Gad-Free) software application was awarded a patent by the US Patent and Trademark Office.
The technology eliminates the need to intravenously inject contrast agent during medical imaging procedures, the company said, adding that the patent underscores the potential of artificial intelligence (AI), its ability to streamline workflows, enhance diagnostic quality, and improve patient safety.
READ: IQ-AI says Los Angeles County Hospital has bought subsidiary's brain tumour imaging platform
“The 0% contrast dose approach offers remarkable benefits which include a more comfortable patient experience, and the alleviation of potential problems arising from the long-term effects of repeated Gadolinium-based contrast agent (GBCA) use”, the company said in a statement.
"This patented technology now available in the IQAI portfolio has the potential to directly impact routine clinical workflows globally", added chief executive Trevor Brown.